ArticleBlood2005
Lentiviral delivery of short hairpin RNAs protects CD4 T cells from multiple clades and primary isolates of HIV.
Article in Blood, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 107 citations in OpenAlex.
- Systemic Treatment with siRNA Targeting Gamma-Secretase Activating Protein Inhibits Amyloid-β Accumulation in Alzheimer's Disease.Biomaterials research · 2024Article
- Evaluation of the Elements of Short Hairpin RNAs in Developing shRNA-Containing CAR T Cells.Cancers · 2023Article
- Editing out HIV: application of gene editing technology to achieve functional cure.Retrovirology · 2021Review
- CRISPR-Cas13a Inhibits HIV-1 Infection.Molecular therapy. Nucleic acids · 2020Article
- Modern biotechnology-based therapeutic approaches against HIV infection.Biomedical reports · 2017Article
- Intranasal drug delivery of small interfering RNA targeting Beclin1 encapsulated with polyethylenimine (PEI) in mouse brain to achieve HIV attenuation.Scientific reports · 2017Article
- Electro-Magnetic Nano-Particle Bound Beclin1 siRNA Crosses the Blood-Brain Barrier to Attenuate the Inflammatory Effects of HIV-1 Infection in Vitro.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2017Article
- Fragile X mental retardation protein promotes astrocytoma proliferation via the MEK/ERK signaling pathway.Oncotarget · 2016Article
- Lentivirus pre-packed with Cas9 protein for safer gene editing.Gene therapy · 2016Article
- Development of Lentiviral Vectors Simultaneously Expressing Multiple siRNAs Against CCR5, vif and tat/rev Genes for an HIV-1 Gene Therapy Approach.Molecular therapy. Nucleic acids · 2016Article
- Inhibition of HIV-1 by a Lentiviral Vector with a Novel Tat-Inducible Expression System and a Specific Tropism to the Target Cells.Human gene therapy · 2015Article
- Multiplexing seven miRNA-Based shRNAs to suppress HIV replication.Molecular therapy : the journal of the American Society of Gene Therapy · 2015Article
- RNA interference approaches for treatment of HIV-1 infection.Genome medicine · 2015Article
- CCR5 Gene Editing of Resting CD4(+) T Cells by Transient ZFN Expression From HIV Envelope Pseudotyped Nonintegrating Lentivirus Confers HIV-1 Resistance in Humanized Mice.Molecular therapy. Nucleic acids · 2014Article
- A Conserved Target Site in HIV-1 Gag RNA is Accessible to Inhibition by Both an HDV Ribozyme and a Short Hairpin RNA.Molecular therapy. Nucleic acids · 2014Article
- The productive entry pathway of HIV-1 in macrophages is dependent on endocytosis through lipid rafts containing CD4.PloS one · 2014Article
- Silencing sexually transmitted infections: topical siRNA-based interventions for the prevention of HIV and HSV.Infectious diseases in obstetrics and gynecology · 2014Review
- Production of highly potent recombinant siRNAs in Escherichia coli.Nature protocols · 2013Article
- Efficient and specific gene knockdown by small interfering RNAs produced in bacteria.Nature biotechnology · 2013Article
- Improvement in efficacy of DNA vaccine encoding HIV-1 Vif by LIGHT gene adjuvant.Viral immunology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
Viral heterogeneity is a major hurdle for potential therapeutic use of RNA interference (RNAi) against HIV-1. To determine the extent of RNAi tolerance to mutations, we tested 3 viral target sites with differing propensity for mutations: a highly variable rev sequence, a gag sequence conserved only among clade B isolates, and a vif sequence highly conserved across clades. Lentiviral expression of all 3 shRNAs inhibited replication of the homologous HIV(IIIB) strain. However, they differed in their ability to protect primary CD4 T cells against multiple isolates within and across HIV clades. The least conserved rev sequence inhibited only 2 of 5 clade B isolates. The gag sequence (conserved within clade B) protected 5 of 5 clade B isolates but not other clade viruses with 2 or 3 mutations in the central region. In contrast, the vif sequence, which was conserved across clades except for single mutations at positions 14 and 17, inhibited viruses from 5 different clades. Moreover, siRNAs with introduced mutations at sites of gag sequence polymorphisms showed reduced antiviral activity, whereas mutations in vif siRNA only modestly decreased silencing. Thus, although 1 or 2 mutations at peripheral sites are tolerated, mutations in the central target cleavage region abolish RNAi activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.